Michael L. LeFevre, MD, MSPH, was recently appointed chair of the U.S. Preventive Services Task Force (USPSTF), replacing Virginia A. Moyer, MD, MPH. He will serve a 1-year term.
An independent volunteer panel of 16 experts in prevention, evidence-based medicine, and primary care, the USPSTF works to improve the health of all Americans by making recommendations on a variety of clinical services such as cancer screenings and preventive medications to primary care physicians. LeFevre has been a USPSTF member since 2005 and served as co–vice chair for the past 3 years.
LeFevre is vice chair of the Department of Family and Community Medicine at the University of Missouri School of Medicine in Columbia. A practicing family physician and researcher, he was elected to the Institute of Medicine of the National Academies in 2011.
Bruno Strigini, MBA, PharmD, was appointed president of Novartis Oncology (Basel, Switzerland), effective June 1. He replaces Hervé Hoppenot, who became president and CEO of Incyte earlier this year. Novartis Oncology includes more than 8,000 employees in 55 countries and markets nine key products, not counting those that it will acquire from GlaxoSmithKline as part of a deal announced in April.
Strigini joined Novartis from Merck & Co., where he most recently served as president for Europe and Canada. Prior to Merck, he worked for a number of companies, including Schering-Plough, UCB-Celltech, and SmithKline Beecham. He has 25 years of experience in pharmaceuticals, animal health, over-the-counter medicines, and vaccines.
Strigini is a member of the Executive Committee of the European Federation of Pharmaceutical Industries & Associations, as well as a member of the Académie Nationale de Pharmacie in France.
For more news on cancer research, visit Cancer Discovery online at http://CDnews.aacrjournals.org.